The anal fistula treatment market will show a rapid growth due to the rising cases of inflammatory bowel diseases such as crohn’s disease and ulcerative colitis, launch of new products and growing demand of non-surgical methods such as fibrin glue injection, adipose-derived stem cells therapy.
There has been an increasing prevalence of anal fistula cases as it remains a perplexing condition for the colorectal surgeon. As per GBD 2017 Inflammatory Bowel Disease Collaborators, there were 6.8 million cases of inflammatory bowel disease IBD globally. The age-standardised prevalence rate increased from 79.5per 100000 population in 1990 to 84.3 per 100 000 population in 2017.
In addition, there is a rise in demand for safe and effective treatment with no chance of recurrence and fewer side effects that is propelling the key industry players to introduce advanced drugs and devices.
Key Market Trends
Surgical is Expected to Dominate the Anal Fistula Treatment Market of Treatment Type Segment During the Forecast Period
The surgical treatment for an anal fistula is found to be associated with low recurrence rates, minimal incontinence and good quality of life. The best option is found to depend on the position of fistula and whether it's a single channel or branches off in different directions. Surgical procedures include fistulotomy, bioprosthetic plugs, advancement flap procedures, seton techniques, and new techniques such as LIFT and FiLaC therapy. The most common type of surgery for anal fistulas is a fistulotomy.
The surgical segment is found dominating the anal fistula treatment market due to the increasing incidences of fistula induced infections, rise in demand of safe and effective treatment helps to drive the overall market.
North America is Found Leading the Anal Fistula Treatment Market
North America is found dominating the anal fistula market due to a large number of patient population with inflammatory bowel diseases, early adoption of new technologies, and high health care expenditure by the public and private sectors in the United States. There are approximately 70,000 new cases of IBD being diagnosed every year in the United States, and this high rate of IBD cases are increasing every year that has helped in the overall growth of the market. However, increasing demand for anal fistula treatment is creating opportunities and increasing awareness about the treatment in the market.
In Asia Pacific region, there is also an increased incidence of conditions such as Crohn’s disease and increased awareness about these conditions that are expected to propel the anal fistula treatment market during the forecast period.
The presence of a considerable number of companies is found significantly contributing to market growth. Market players are actively participating in new product launches, collaboration and development to expand their market share. For instance, in February 2018, AMI has launched FiXcision instrument, which consists of the guide, circular blade, probe and base plate for the precise treatment of anal fistulas.
Key players in the anal fistula treatment market are Cook Medical, KARL STORZ SE & Co. KG, Medtronic plc, Pfizer Inc., W. L. Gore & Associates, Inc., Biolitec AG and others.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Cases of Inflammatory Bowel Diseases (IBD) Such As Crohn's Disease and Ulcerative Colitis
4.2.2 Launch of New Products
4.2.3 Growing Demand of Non-Surgical Methods Such as Fibrin Glue Injection, Adipose-derived Stem Cells Therapy
4.3 Market Restraints
4.3.1 High Cost Associated With the Procedure
4.3.2 Lack of Awareness about Anal Fistula Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Non Surgical
5.2 By Application
5.2.1 Intersphincteric Fistula
5.2.2 Transsphincteric Fistula
5.2.3 Suprasphincteric Fistula
5.3 By End User
5.3.2 Ambulatory Surgical Centers
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6.1.1 Pfizer, Inc.
6.1.2 Cook Medical
6.1.3 KARL STORZ SE & Co. KG
6.1.4 Medtronic plc
6.1.5 AstraZeneca Plc
6.1.6 W. L. Gore & Associates, Inc (Gore Medical)
6.1.7 Biolitec AG
A selection of companies mentioned in this report includes:
- Pfizer, Inc.
- Cook Medical
- KARL STORZ SE & Co. KG
- Medtronic plc
- AstraZeneca Plc
- W. L. Gore & Associates, Inc (Gore Medical)
- Biolitec AG